Inhibikase Therapeutics (IKT) AI Stock Analysis

• Market Cap: $189.18M
• Dividend Yield: N/A
• Average Volume (3M): 132.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -100.00%
• EPS Growth: 79.01%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 121,267,044
• 10 Day Avg. Volume: 124,469
• 30 Day Avg. Volume: 132,718
• PEG Ratio: 0.12
• Price to Book (P/B): 2.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.77
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.10K
• Enterprise Value/Ebitda: -1.45
• 1Y Price Target: $6.20
• Price Target Upside: 297.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $1.50 ▼(-3.85% Downside)

The score is held back primarily by the absence of revenue, recurring losses, and ongoing cash burn, despite a low-debt balance sheet. Technical indicators show strong upward momentum, and recent financing plus Phase 3 plans improve operational runway and catalyst potential, but dilution and loss-driven valuation constraints keep the overall score moderate.

Positive Factors

Low Leverage / Strong Balance Sheet

A near-zero debt profile and a conservatively financed balance sheet reduce financial risk and preserve flexibility to fund clinical programs through equity or partnerships. Low leverage supports runway extension and limits interest burden, a durable advantage for a cash-burning biotech in development.

IKT-001 Advancing to Pivotal Phase 3

Progression to a global Phase 3 is a structural milestone that can materially de-risk the program if successful, enabling regulatory path to approval, potential partner interest, and clearer commercial prospects. A pivotal study creates multi-quarter strategic focus and potential for future licensing or launch planning.

Completed / Planned Capital Raise to Support Trials

Securing significant equity financing specifically to support clinical advancement materially extends operational runway and funds the Phase 3 program. Reliable access to capital is a durable operational enabler for a development-stage biotech dependent on trial spend rather than product revenues.

Negative Factors

No Revenue / Structural Losses

The company remains pre-revenue with large, recurring net losses, meaning long-term value depends entirely on R&D outcomes or successful partnerships. Persistent negative profitability requires ongoing financing and increases execution risk tied to clinical and regulatory success rather than cash-generating operations.

High Operating Cash Burn

Sustained negative operating cash flow and rising absolute burn increase dependency on external funding and shorten independent runway. Higher cash consumption pressures strategic choices, can force dilutive financings or cutbacks in programs, and is a persistent structural constraint for a small clinical-stage biotech.

Ongoing Dilution Risk

Aggressive equity programs and recent offerings signal reliance on share issuance to fund operations, creating ongoing dilution risk for existing shareholders. Repeated capital raises can erode per-share value and may complicate long-term investor returns unless clinical readouts or partnerships materially improve fundamentals.

Inhibikase Therapeutics Business Overview & Revenue Model

Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

How the Company Makes Money

Inhibikase Therapeutics makes money through the development and commercialization of its pharmaceutical products. The company's revenue model is primarily based on advancing its drug candidates through clinical trials and achieving successful regulatory approvals. Key revenue streams include potential partnerships with larger pharmaceutical companies for the co-development or licensing of its therapies, as well as possible future revenues from product sales once the drugs reach the market. Additionally, the company may receive funding through research grants, collaborations, and milestone payments from strategic alliances, which help support its research and development efforts.

Inhibikase Therapeutics Financial Statement Overview

Summary

Overall fundamentals reflect a development-stage biotech: the income statement is very weak with no revenue in recent periods and large recurring losses, and cash flow shows persistent operating and free cash flow burn. The balance sheet is the main offset, with essentially no debt and a conservatively financed structure, though equity has declined as losses continue.

Income Statement

The income statement remains very weak, with no revenue in TTM (Trailing-Twelve-Months) and 2024, and large recurring losses (TTM net loss of ~$47.7M; 2024 net loss of ~$27.5M). Profitability is structurally negative (negative gross profit in most periods and deeply negative margins where revenue exists), reflecting a business still in heavy investment mode. A modest positive is that losses were smaller in 2024 vs. 2023, but the return to zero revenue and the larger TTM loss versus 2024 highlights continued earnings volatility.

Balance Sheet

The balance sheet is a relative strength: debt is essentially zero in TTM (Trailing-Twelve-Months) and very low historically, keeping financial risk from leverage minimal. Equity is sizeable (TTM equity ~$72.9M; 2024 ~$94.9M) versus assets (TTM assets ~$79.6M), suggesting a conservatively financed structure. The key weakness is ongoing value erosion from losses (negative returns on equity across all periods) and a notable equity decline from 2024 to TTM, consistent with continued cash burn.

Cash Flow

Cash flow is pressured by persistent operating cash burn (TTM operating cash flow of about -$25.6M; 2024 about -$19.1M), and free cash flow is also negative, indicating the business is not yet self-funding. While free cash flow improved versus the prior period in TTM (positive growth rate), the absolute burn rate remains high and appears to have stepped up versus 2024. A stabilizing point is that free cash flow tracks net loss fairly closely, suggesting losses are largely reflected in cash usage rather than being masked by large non-cash items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	260.50K	123.44K	3.10M	698.47K
Gross Profit	-67.07K	-26.27K	-13.36M	116.72K	-8.26M	-195.33K
EBITDA	-50.95M	-27.49M	-19.91M	-18.05M	0.00	0.00
Net Income	-47.66M	-27.52M	-19.03M	-18.05M	-14.79M	-2.85M
Balance Sheet
Total Assets	79.59M	98.60M	14.51M	24.94M	42.47M	14.78M
Cash, Cash Equivalents and Short-Term Investments	77.32M	97.54M	13.25M	23.05M	40.75M	13.95M
Total Debt	0.00	110.52K	622.00K	351.29K	248.91K	319.00K
Total Liabilities	6.70M	3.73M	3.53M	3.90M	4.05M	5.00M
Stockholders Equity	72.90M	94.87M	10.98M	21.04M	38.42M	9.78M
Cash Flow
Free Cash Flow	-25.62M	-19.15M	-18.10M	-17.59M	-14.30M	-1.13M
Operating Cash Flow	-25.62M	-19.15M	-18.09M	-17.35M	-14.30M	-1.13M
Investing Cash Flow	-36.61M	-37.00M	11.66M	-16.01M	0.00	0.00
Financing Cash Flow	99.58M	103.48M	8.41M	-204.77K	41.09M	15.06M

Inhibikase Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IKT, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.66, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.74 is Neutral, neither overbought nor oversold. The STOCH value of 21.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IKT.

Inhibikase Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IKT	54 Neutral	$189.18M	-2.77	-131.71%	―	-100.00%	79.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$202.71M	-0.97	―	―	-63.96%	-28.50%
ANIX	49 Neutral	$97.47M	-8.17	-62.16%	―	―	11.78%
TCRX	49 Neutral	$54.56M	-0.81	-76.44%	―	-10.03%	11.06%
SPRO	48 Neutral	$129.02M	-2.89	-95.29%	―	-67.38%	-1076.54%
ATOS	43 Neutral	$45.55M	-1.51	-48.89%	―	―	-9.42%

Inhibikase Therapeutics Corporate Events

Inhibikase Updates ATM Equity Program to Raise Capital

On December 19, 2025, Inhibikase Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to update its existing at-the-market equity offering program, enabling the company to sell up to $185 million of its common stock from time to time through Jefferies LLC as sales agent under a previously executed open market sale agreement. The filing, made under an already effective shelf registration statement, reinforces the company’s ability to raise additional capital as needed, which may support ongoing operations and development programs while potentially diluting existing shareholders depending on the scale and timing of future share issuances.

The most recent analyst rating on (IKT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Inhibikase Therapeutics Announces $93.6 Million Stock Offering

On November 20, 2025, Inhibikase Therapeutics, Inc. announced an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to raise approximately $93.6 million, with potential to increase to $107.7 million if the underwriters exercise their option in full. This financial move is part of the company’s strategy to support its clinical trial advancements, including the progression of IKT-001 to a global pivotal Phase 3 clinical trial in PAH, reflecting its commitment to expanding its therapeutic offerings in the biotechnology sector.

The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study

On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension, expected to begin in the first quarter of 2026. The study, named IMPROVE-PAH, will be conducted in two parts, with Part A focusing on pulmonary vascular resistance and Part B on the 6-minute walk distance. The company believes this adaptive study design offers significant advantages, such as a dose-titration phase and uninterrupted enrollment. Additionally, Inhibikase terminated its ATM Prospectus but maintained the Sales Agreement with Jefferies LLC, indicating a strategic shift in its financial operations.

The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.